BUSINESSGUARDIAN US
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.
Mentioned
Related Signal
Adjacent reporting
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- GSK in talks to buy cancer biotech Nuvalent for more than $9bn
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion